MannKind Corporation to Participate in the BTIG Biotechnology Conference
August 01 2022 - 6:00AM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of innovative
therapeutic products for patients with endocrine and orphan lung
diseases, announced today that its Chief Executive Officer, Michael
Castagna, PharmD, and Chief Financial Officer, Steven Binder will
participate in the BTIG Biotechnology Conference taking place on
Monday, August 8 – Tuesday, August 9, 2022.
This conference is being hosted by BTIG, a global financial
services firm specializing in institutional trading, investment
banking, research, and related brokerage services. BTIG’s Corporate
Access program hosts client events across the consumer, digital
assets, energy and infrastructure, financials, healthcare, real
estate, and technology sectors.
Management will be participating in one-on-one meetings
throughout the event. To join the conference and arrange a meeting
with management, please email info@btig.com.
About MannKind CorporationMannKind Corporation
(Nasdaq: MNKD) focuses on the development and commercialization of
therapeutic and convenient products for patients with endocrine and
orphan lung diseases. MannKind is currently commercializing
Afrezza® (insulin human) Inhalation Powder, the Company’s first
FDA-approved product and the only inhaled ultra rapid-acting
mealtime insulin in the United States, where it is available by
prescription from pharmacies nationwide. Afrezza is also available
by prescription in Brazil, where it is commercialized by the
Company’s partner, Biomm SA. MannKind was established in 1991, and
is located in Danbury, Conn., and Westlake Village, Calif. The
Company also employs field sales and medical representatives across
the U.S. Please visit mannkindcorp.com to learn more.
Contact:Rose Alinaya, Investor Relations(818) 661-5000Email:
ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2023 to Jul 2024